{"id":"W2895953827","doi":"10.1007/s40263-018-0579-4","title":"From LBR-101 to Fremanezumab for Migraine","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Calcitonin gene-related peptide; Migraine; Chronic Migraine; Medicine; Calcitonin; Monoclonal antibody; Drug development; Pharmacology; In vivo; Receptor; Bioinformatics; Neuroscience; Antibody; Neuropeptide; Immunology; Drug; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002404837,0.0005327089,0.002591977,0.0002260783,0.0001284259,0.00002097738,0.0002479635,0.0003214055,0.0004766836],"category_scores_gemma":[0.0004185277,0.0003880608,0.001116688,0.0002759651,0.00008426948,0.00002258494,0.0001491602,0.0002819472,0.001368587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001395456,"about_ca_system_score_gemma":0.0003059572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001971805,"about_ca_topic_score_gemma":0.0001241416,"domain_scores_codex":[0.997911,0.00003842303,0.0006308245,0.000677698,0.0002580614,0.0004839411],"domain_scores_gemma":[0.9981731,0.000370474,0.0001772111,0.0008105248,0.0001907304,0.000277997],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001945369,0.00004980815,9.572884e-7,0.009255104,0.0004804904,0.000008192319,0.001400335,2.311538e-9,4.32362e-7,0.00004478706,0.7690604,0.21968],"study_design_scores_gemma":[0.0005542579,0.0002991472,0.000004231609,0.01352908,0.002620901,0.00001430542,0.0002435143,9.465279e-7,0.000002952769,0.0001445662,0.9822185,0.0003675938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002354312,0.9860271,0.0000921299,0.001179149,0.0001795239,0.002321536,0.0005216789,0.0001061639,0.009549136],"genre_scores_gemma":[0.00000372486,0.9225251,0.002575447,0.0009102725,0.005846045,0.0005470203,0.0008355981,0.0001124982,0.06664427],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2193124,"threshold_uncertainty_score":0.9998571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08518251319761845,"score_gpt":0.4039379044625236,"score_spread":0.3187553912649052,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}